Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
27,265,524
-
Shares change
-
+6,737,615
-
Total reported value, excl. options
-
$391,622,872
-
Value change
-
+$102,455,955
-
Put/Call ratio
-
35.16%
-
Number of buys
-
79
-
Number of sells
-
-38
-
Price
-
$14.37
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q2 2017
131 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q2 2017.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27,265,524 shares
of 236,234,693 outstanding shares and own 11.54% of the company stock.
Largest 10 shareholders include EAGLE ASSET MANAGEMENT INC (3,525,685 shares), BlackRock Inc. (2,744,607 shares), Nantahala Capital Management, LLC (2,148,623 shares), Novo Holdings A/S (1,814,289 shares), VANGUARD GROUP INC (1,436,163 shares), FIRST MANHATTAN CO (1,188,500 shares), PERCEPTIVE ADVISORS LLC (1,100,000 shares), FMR LLC (1,036,955 shares), RENAISSANCE TECHNOLOGIES LLC (1,025,300 shares), and STATE STREET CORP (946,888 shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.